Welcome to CESPHN

In order to tailor the site to your needs, please click the button that relates best to you.

So long as you have cookies enabled you will only need to do this once. However, you can change your selection at any time using the dropdown navigation option above the CESPHN logo, top left.

Close this window
IMPORTANT NOTICE

This post is not the latest immunisation update and therefore may contain information or advice that is out of date. Please see our most recent update here.

Immunisation weekly update – 21 July 2021

21 July 2021

20190319 Immunisation needle icons 31

COVID-19 vaccination update: fighting the Delta variant

Register here for the webinar this Thursday 22 July 7.00pm – 8.30pm

Join Associate Professor Nicholas Wood, Associate Director, Clinical Research and Services, NCIRS Senior Staff Specialist as he discusses COVID-19 vaccines and the conversations GPs need to be having with their patients

  • practical information to assist GPs in having the AstraZeneca risk/benefit conversation
  • the link between myocarditis and Pfizer vaccination
  • impacts different strains of COVID-19 has on the effectiveness of vaccines
  • the conversation and current data around mixing COVID-19 vaccines

You will also hear practical tips and insights from a local GP on how they run their vaccination clinic, and then from an RN on how they are running their nurse led clinics and drawing up vaccines. 

Excess AstraZeneca vaccines

Primary care COVID-19 vaccination sites may choose to transfer AstraZeneca vaccines from one participating vaccination site to another for a range of reasons, including to support unmet demand at another site or to manage an oversupply of stock. 

Practices with an oversupply of AstraZeneca vaccine stock on hand are encouraged to contact CESPHN via email at coronavirus@cesphn.com.au to help facilitate transfer to practices to who required additional AstraZeneca vaccine supply. 

New pregnancy advice for women who received their first dose of COVID-19 Vaccine AstraZeneca and are now pregnant

New guidance advises that for women who received their first dose of COVID-19 Vaccine AstraZeneca and are now pregnant, can receive their second dose of either COVID-19 Vaccine AstraZeneca or Comirnaty (Pfizer), although Comirnaty is preferred.

Pregnant women should be routinely offered Comirnaty (Pfizer) at any stage of pregnancy. Pregnant women with COVID-19 have an increased risk of severe illness and adverse pregnancy outcomes. It is noted they are not currently picked up by the eligibility checker, however Pfizer vaccination providers are encouraged to facilitate the vaccination of pregnant women, who are not otherwise eligible, if they have capacity. Comirnaty is the preferred COVID-19 vaccine for women who are pregnant due to the amount of safety data available.

Further information:

%MCEPASTEBIN%